Who
Joseph M. Miller
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, LB Pharmaceuticals; Chief Financial Officer, Aurinia Pharmaceuticals; Chief Financial Officer, Avalo Therapeutics.
In numbers
- Trades disclosed
- 47
- Buys
- 3
- Sells
- 6
- Bought
- $21K
- Sold
- $1.4M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 12 Jul 2018
- Last trade
- 9 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Oct 2026filed 13 Oct 2026 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $533K37,511 at $14.21 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $533K37,511 at $14.21 | filing |
| 27 Feb 2026filed 3 Mar 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —57,229 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,700 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,700 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —57,229 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $467K32,424 at $14.40 | filing |
| 20 Feb 2026filed 23 Feb 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $467K32,424 at $14.40 | filing |
| 2 Jan 2026filed 5 Jan 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —49,038 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $641K40,161 at $15.95 | filing |
| 2 Jan 2026filed 5 Jan 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —49,038 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $641K40,161 at $15.95 | filing |
| 4 Mar 2025filed 4 Mar 2025 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $445K56,154 at $7.92 | filing |
| 3 Mar 2025filed 4 Mar 2025 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —114,711 at $0.00 | filing |
| 3 Mar 2025filed 4 Mar 2025 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $495K61,859 at $8.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —124,393 at $0.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —81,457 at $0.00 | filing |
| 6 Mar 2024filed 7 Mar 2024 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $195K34,811 at $5.60 | filing |
| 20 Feb 2024filed 22 Feb 2024 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —196,153 at $0.00 | filing |
News
Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Cross Above Fifty Day Moving Average – Time to Sell?AUPH · tickerreport.com · 17 Oct 2026Avalo Therapeutics (NASDAQ:AVTX) versus Praxis Precision Medicines (NASDAQ:PRAX) Financial AnalysisAVTX · tickerreport.com · 16 Oct 2026Avalo Therapeutics (NASDAQ:AVTX) Stock Falls 6.6% – Should You Sell?AVTX · dailypolitical.com · 13 Oct 2026Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Crosses Above 50-Day Moving Average – Here's What HappenedAUPH · themarketsdaily.com · 9 Oct 2026Head to Head Contrast: Aurinia Pharmaceuticals (NASDAQ:AUPH) & Puma Biotechnology (NASDAQ:PBYI)AUPH · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name Joseph M. Miller; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.